Several therapies from a range of drug classes are available to address the symptoms of narcolepsy; these symptoms include excessive daytime sleepiness (EDS) and cataplexy. Despite the availability of many pharmacological treatments, a large proportion of patients have inadequate control of their narcolepsy symptoms, leaving opportunity for new agents to address these shortcomings. Given that treatment is highly individualized and complex, understanding the use of current therapies in the nuanced narcolepsy treatment algorithm ahead of anticipated product launches is essential. Our Treatment Algorithms research leverages national patient-level claims data to explore the uptake and use of key therapies in narcolepsy (such as modafinil, armodafinil, psychostimulants, antidepressants, the oxybates) and agents approved for the treatment of EDS or EDS and cataplexy symptoms in narcolepsy (such as Harmony Biosciences’ Wakix, Jazz Pharmaceuticals’ Xyrem and Xywav, and Axsome’s Sunosi) in both newly diagnosed and recently treated patients.
QUESTIONS ANSWERED
CONTENT HIGHLIGHTS
Geographies: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: armodafinil, modafinil, Sunosi, Vyvanse, Xyrem, Xywav, Wakix
Key companies covered: Axsome, Eli Lilly, Harmony Biosciences, Jazz Pharmaceuticals, Takeda, Teva
Key analysis provided:
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
SOLUTION ENHANCEMENT
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.